Reactosome

Biotech, Rewritten from the Nucleus Out

San Francisco, United States · Founded 2023

Employees
1–10
Founded
2023
Business Model
B2B
Last Round
AngelMar 2024
Rounds
1

About

Reactosome is a synthetic cell platform company pioneering programmable molecular compartments called Synthetic Nuclei that combine precision intracellular delivery with on-site RNA and protein production. Unlike viral vectors or lipid nanoparticles, Reactosome proprietary platform can transport complex cargos including large genes and enzymes, enabling localized RNA expression and protein production directly inside the cell. The platform is designed for three application areas: gene therapies for structural and metabolic disorders, localized protein production for regenerative medicine, and bioproduction for pharma, cosmetics, and industrial biotech. The company operates across San Francisco and Berlin.

Summary

Reactosome is a Biotech company based in San Francisco, United States, founded in 2023. Its most recent funding was an Angel round in Mar 2024. Investors include SOSV.

Tech & App Stack

2 technologies & apps tracked

Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

AngelAngel RoundMar 2024

Investors

Similar Companies